South San Francisco, CA · Founded 2018 · Privately Held (backing)
Developer of immunoregulatory medicines designed to restore immune balance in inflammatory diseases through tissue regulatory T cell biology. TRexBio is based in South San Francisco, CA and was founded in 2018. It is valued at about $274 million as of Oct 2026, set by institutional fund marks. It has raised $222 million.
PMV mark · valuation
$274.0M
Oct 2026
Priced at
—
Total raised
$222.1M
Last round
—
Team — not yet on record
No current team members for TRexBio are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of TRexBio with a free account
·The complete investor list: 14 names
·Watch TRexBio: the Monday email on marks, rounds and moves
